Opinion|Videos|December 21, 2023
SEQUOIA: Biomarker Subgroup Analysis on Zanubrutinib in Treatment-Naïve CLL/SLL Without del(17p)
Experts on leukemia review the biomarker subgroup analysis from the SEQUOIA study looking at zanubrutinib in patients with treatment-naïve CLL/SLL without 17p deletion.
Advertisement
Episodes in this series
Advertisement
Related to this article
FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Rusfertide Redefines the Polycythemia Vera Paradigm
2
FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC
3
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
4
Extended Survival Raises New Questions on Imaging and Treatment Intensification in ROS1+ NSCLC
5